Topic：Science and life--A real adventure

Lecturer：PH.D, Professor Wang Yanming

 Case Western Reserve University, US.

Location：Conference room on 4th floor in Administration Building

                  Fuyan Mountain Campus

Time：10:00 am, 21st September 2017

Dr. Yanming Wang has a broad research experience in medicinal chemistry in general and molecular imaging in particular. Following his PhD in chemistry at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, Dr. Wang conducted his postdoctoral research at Duke University. In 1998, Dr. Wang joined the faculty of Radiology at the University of Pittsburgh where his research was focused on radiopharmaceutical development for imaging studies. Over the past decade, his research has focused on the development and application of molecular probes for biomedical imaging based on a variety of imaging modalities including positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), multiphoton microscopy, and near-infrared fluorescent imaging (NIRF). He has developed several imaging agents targeting some important pathological processes such as amyloid deposition in Alzheimer’s disease and aging, myelin damage and repair in multiple sclerosis, DNA damage and repair as well as MET receptor expression in cancer. He was the first to design and synthesize PIB, an amyloid-imaging agent that has now been widely used in clinical trials worldwide. He is also noted for his recent work on longitudinal imaging of myelination based on multiple imaging modalities.In addition, Dr. Wang is Director of Radiopharmaceutical Research at Case Western Reserve University and provides imaging agents for many clinical and preclinical studies.  

Over the past 15 years, Dr. Yanming Wang’s research has been focused on the development and application of molecular probes for biomedical imaging based onPET, SPECT, MRI, multiphoton microscopy, and near-infrared fluorescent imaging. He has developed several imaging agents targeting some important disease processes including amyloid deposition in Alzheimer’s disease, myelin damage and repair in multiple sclerosis, DNA damage and repair as well as MET receptor expression in cancer. He was the co-inventor of PIB, an amyloid-imaging agent that has now been widely used in clinical trials worldwide. He is considered as a pioneer in PET imaging of myelination.